US FDA Calls Foul On CSL Behring Hemophilia Drug Promo

Idelvion promotional materials misleadingly imply that patients can engage in high-risk activity without consequences; first letter from US biologics promo branch in three years.

Soccer-Player_736762759_1200.jpg

In a rare action, the US FDA has objected to a sports image in a drug promotion for suggesting that a patient could engage in the activity without risk of injury.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance